Why Cancer History Requires Special Consideration
IGF-1 (insulin-like growth factor 1) — the primary downstream marker of GH activity — has complex relationships with cancer biology. IGF-1 promotes cell growth and proliferation, which is beneficial for tissue repair but is also a property that could theoretically support tumor growth in susceptible individuals. This is a theoretical concern with genuine biological basis, not unfounded paranoia.
GH Secretagogues and Cancer Risk
The relationship between GH, IGF-1, and cancer risk in healthy adults is nuanced and not clearly established. Large epidemiological studies on GH replacement therapy have not shown a clear increased cancer incidence at physiological replacement doses. However, anyone with a personal or strong family history of certain cancers — particularly prostate, breast, and colorectal — requires careful physician assessment before GH-axis stimulating peptides are prescribed.
BPC-157 and Cancer
BPC-157’s angiogenic effects (promoting new blood vessel formation) also require consideration in the context of cancer history, as angiogenesis supports tumor growth as well as tissue repair. Some preclinical research has actually found anti-tumor effects for BPC-157, but this research is not sufficient to make claims about cancer safety or treatment.
The Non-Negotiable: Oncologist Consultation
Anyone with an active cancer diagnosis, recent cancer history, or strong family history of cancer must discuss any peptide therapy consideration with their oncologist before proceeding. My Body Labs’ physicians will take a detailed cancer history during the intake process and will decline to prescribe certain protocols if the risk-benefit assessment is unfavorable.